AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Incremental Kidney and Glycemic Outcomes Associated with GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Therapy versus SGLT2 Inhibitor Monotherapy in Adults with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease

By Adjei-Wiafe E, Blankson GA, Ansah EN et al.

Background: Patients with type 2 diabetes mellitus (T2DM), heart failure (HF), and chronic kidney disease (CKD) remain at high risk for renal deterioration, glycaemic emergencies, and adverse cardiovascular outcomes despite contemporary therapy. Although sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiorenal outcomes, the incremental benefit of adding glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy remains uncertain. Objective: To compare renal, glycaemic, and cardiovascular outcomes between SGLT2i monotherapy and combined GLP-1RA/SGLT2i therapy in adults with T2DM, HF, and CKD. Methods: We performed a retrospective propensity score-matched cohort study using the TriNetX Research Network. Adults aged ≥18 years with T2DM, HF, and CKD stages 3a-4 without baseline ESRD were included. Patients receiving GLP-1RA plus SGLT2i therapy were compared with those receiving SGLT2i monotherapy. After balancing demographics, comorbidities, and cardiovascular and diabetes medications using propensity score matching, 20,059 patients were included in each cohort from an initial population of 71,970 eligible patients. Outcomes were assessed from 30 days to 5 years after treatment initiation. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated for renal, glycaemic, cardiovascular, and mortality outcomes. Results: Combination therapy was associated with lower risk of composite renal events (HR 0.894, 95% CI 0.853-0.937; p<0.001), AKI (HR 0.886; p<0.001), ESRD progression (HR 0.895; p=0.003), MACE (HR 0.842; p<0.001), all-cause mortality (HR 0.706; p<0.001), and HF exacerbation (HR 0.849; p<0.001). Composite glycaemic events were modestly increased (HR 1.094, 95% CI 1.015-1.179; p=0.019), driven by DKA/HHS without coma (HR 1.112; p=0.046). Conclusions: In adults with T2DM, HF, and CKD, GLP-1RA/SGLT2i therapy was associated with improved renal and cardiovascular outcomes compared with SGLT2i monotherapy. However, the modest increase in glycaemic events warrants careful clinical monitoring and prospective evaluation.

doi.org/10.1161/circ.154.suppl_1.8980Interventions

AgingResearch.News